Reply to "Double-counting of effect sizes and inappropriate exclusion of studies in "The influence of vitamin D supplementation on IGF-1 levels in humans: A systematic review and meta_analysis"
View/ Open
Publisher version (Check access options)
Check access options
Date
2021Author
Kord-Varkaneh, HamedRinaldi, Giulia
Hekmatdoost, Azita
Fatahi, Somaye
Tan, Shing Cheng
Shadnoush, Mahdi
Khni, Vahid
Mousavi, Seyed Mohammad
Zarezadeh, Meysam
Salamat, Shekoufeh
Bawadi, Hiba
Rahmani, Jamal
...show more authors ...show less authors
Metadata
Show full item recordAbstract
Dear Editor,
We appreciate the comments provided to us in the letter from Amiri et al. We would like to offer some clarifications in response to the comments.
Firstly, the authors claimed that we included the control group more than once from the same publication including different arms. The authors also identified mistakes made during data screening and expressed concerns that the mistakes would lead to errors within our analysis (Kord-Varkaneh et al., 2020). We sincerely thank the authors for pointing out these mistakes. In response, based on The Cochrane Handbook for Systematic Reviews, we have now reanalyzed the results by combining the intervention groups to create a single pair-wise comparison and updated our meta-analysis as displayed below. We initially excluded Sorva, Antti et al. from our study because based on our inclusion criteria we only included studies that had more than 10 participants in each group (Sorva et al., 1994), although we did not originally include this criterion in our publication (Kord-Varkaneh et al., 2020). However, after including Norenstedt, S. et al. and Sinha-Hikim, I. et al. (Sinha-Hikim et al., 2015; Norenstedt et al., 2013) our overall effect size changed from (WMD: 4 ng/ml, 95 % CI: -4 to 11, p = 0.35) to (WMD: 1.01 ng/ml, 95 % CI: --6.78 to 8.81, p = 0.799) without a change in overall significance (Fig. 1). In addtion, subgroup analyses showed that vitamin D dosage ≤1000 IU/day (WMD: 11.36 ng/ml, 95 % CI: 1.57–21.16, I2 = 79 %) significantly increased IGF-1 than vitamin D dosage <1000 IU/day (WMD: -2.8 ng/ml, 95 % CI: -7.02 to 1.6, I2 = 51 %). Moreover, an intervention duration of ≤12 weeks (WMD: 9.92 ng/ml, 95 % CI: 3–16.83, I2 = 77 %) significantly increased IGF-1 compared to a duration of <12 weeks (WMD: -5.43 ng/ml, 95 % CI: -10.25 to -0.61, I2 = 0.0 %). In addition, baseline serum vitamin D (<20 ng/mL vas ≥20 ng/mL) we did not observe significantly.
Collections
- Human Nutrition [404 items ]
Related items
Showing items related by title, author, creator and subject.
-
25-Hydroxyvitamin D Concentrations and Clostridium difficile Infection: A Meta-Analysis
Furuya-Kanamori, L.; Wangdi, K.; Yakob, L.; McKenzie, S.J.; Doi, S.A.R.; Clark, J.; Paterson, D.L.; Riley, T.V.; Clements, A.C.A.... more authors ... less authors ( SAGE Publications Inc. , 2017 , Article)Background: Well-known risk factors for Clostridium difficile infection (CDI) are exposure to antibiotics and gastric acid suppressants. Recent studies have provided some evidence of an association between hypovitaminosis ... -
Prospective cohort study of vitamin D deficiency in pregnancy: Prevalence and limited effectiveness of 1000 IU vitamin D supplementation
Abdelmageed, Rasha Mohammed; Hussein, Suha Majeed Mohammed; Anamangadan, Shamil Mohamed; Abdullah, Rola Walid Mahmoud; Rauf, Lubna; AlFehaidi, Al Anoud Saleh; Hamed, Ehab... more authors ... less authors ( SAGE , 2024 , Article)Background: Vitamin D deficiency is highly prevalent worldwide among pregnant women. Although vitamin D supplementation is effective in improving vitamin D status, the safety and optimal dosing of vitamin D supplementation ... -
Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians
Hamadeh, IS; Shahin, MH; Lima, SM; Oliveira, F; Wilson, L; Khalifa, SI; Langaee, TY; Cooper-DeHoff, RM; Cavallari, LH; Johnson, JA... more authors ... less authors ( Blackwell Publishing Ltd , 2016 , Article)Genotype-based algorithms that include VKORC1 and CYP2C9 genotypes are less predictive of warfarin dose variability in Africans as opposed to Europeans. Polymorphisms in GGCX, FPGS, or STX1B are associated with warfarin ...